Login to Your Account

Otonomy sees shares plummet as Otividex falls short in Meniere's trial

By Michael Fitzhugh
Staff Writer

Wednesday, August 30, 2017

More than seven years after first testing its Meniere's disease candidate, Otividex, in patients with the inner ear disorder, Otonomy Inc. is immediately suspending development of the specially formulated steroid after it proved no better than a placebo in reducing both the number and severity of vertigo episodes in the first of two phase III trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription